Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Prospective Double-blind, Cross-over Phase 3 Study to Evaluate the Efficacy and Safety of 0.04 mmol Gd/kg Body Weight of Gadoquatrane for MRI in Adults With Known or Suspected Pathology of Any Body Region (Except CNS), Compared to 0.1 mmol Gd/kg Approved Macrocyclic Gadolinium-based Contrast Agents (GBCAs)

Next Previous
Trial Profile

A Multicenter, Randomized, Prospective Double-blind, Cross-over Phase 3 Study to Evaluate the Efficacy and Safety of 0.04 mmol Gd/kg Body Weight of Gadoquatrane for MRI in Adults With Known or Suspected Pathology of Any Body Region (Except CNS), Compared to 0.1 mmol Gd/kg Approved Macrocyclic Gadolinium-based Contrast Agents (GBCAs)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 23 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gadobutrol (Primary) ; Gadoquatrane (Primary) ; Gadoterate-meglumine (Primary) ; Gadoteridol (Primary)
  • Indications Brain disorders; Spinal cord disorders
  • Focus Diagnostic use; Registrational
  • Acronyms Quanti OBR
  • Sponsors Bayer

Most Recent Events

  • 17 Jun 2025 According to a Bayer Media Release,announced the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for gadoquatrane for contrast-enhanced magnetic resonance imaging of the CNS and other body regions in adults and pediatric patients including term neonates. The submission of gadoquatrane to the US FDA is based on positive data from the pivotal Phase III QUANTI studies.
  • 02 Jun 2025 According to a Bayer Media Release, company announced the submission of a marketing authorization application to the Ministry of Health, Labour, and Welfare in Japan for its investigational contrast agent gadoquatrane for contrast enhancement in MRI to detect and visualize known or suspected pathologies in all body regions and the central nervous system (CNS) in adults and pediatric patients including neonates. The submission is based on positive data from the pivotal Phase III QUANTI studies.
  • 10 Jan 2025 According to Bayer Media Release, Bayer plans to submit a comprehensive data package which will include the QUANTI study results to health authorities worldwide to secure marketing authorization.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top